S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

Ottesen, Ninja Meinhard; Meluken, Iselin; Frikke‐Schmidt, Ruth; Plomgaard, Peter; Scheike, Thomas; Kessing, Lars Vedel; Miskowiak, Kamilla Woznica; Vinberg, Maj

doi:10.1016/j.jad.2020.05.015

Cited by 5 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, low plasma or serum levels of BDNF were identified in patients suffering from ADs (Aldoghachi et al 2019;Suliman et al 2013;Schröter et al 2020). Conversely, a recent twin study has failed to confirm the relationship between low BDNF levels and DD (Ottesen et al 2020). Our results are consistent with the prior findings from meta-analysis aimed at the study of rs6265 in patients with major depression (Verhagen et al 2010).…”

Section: Discussionsupporting

confidence: 88%

“…Next, some studies reported changes in BDNF pathway affected by taking pharmacotherapy (Chen et al 2010). Other factors have been also outlined, such as the activity of the disorder (acute vs. chronic phase), sample size, group differences (e.g., mean age), errors in the selection or implementation of laboratory techniques, even effects of exercise (Ottesen et al 2020;Szuhany and Otto 2020).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of 5-HTTLPR (insertion/deletion) and BDNF (rs6265) genetic variations in the Slovakian individuals suffering from affective disorders

Bednarova

Čižmáriková²,

Habalová³

et al. 2021

gpb

View full text Add to dashboard Cite

The pathophysiology of affective disorders (AD), including depressive disorders (DD) and anxiety disorders (ANXD), is still unclear. To understand risk factors of the disorders, we evaluated genetic variations of the serotonin reuptake transporter (5-HTTLPR, ins/del) and the brain-derived neurotrophic factor (BDNF, rs6265) in Slovak patients suffering from AD. After genotyping we observed a significantly increased frequency of LS and LL genotypes (5-HTTLPR) in individuals diagnosed with AD compared to controls (OR = 1.99, 95% CI = 1.21-3.27, p = 0.006). There was also a significant relationship between TT (BDNF) genotype and the risk of AD in males (OR = 5.93, 95% CI = 1.42-27.07, p = 0.011). In gene-gene analysis, the LL or LS (5-HTTLPR) and CT or TT (BDNF) genotype combinations had a risk-enhancing effect on AD susceptibility (mainly ANXD in males), while SS (5-HTTLPR) and TT (BDNF) combination had a protective effect on AD risk (mainly ANXD). However, larger prospective studies are needed to confirm our findings.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Evaluation of 5-HTTLPR (insertion/deletion) and BDNF (rs6265) genetic variations in the Slovakian individuals suffering from affective disorders

Bednarova

Čižmáriková²,

Habalová³

et al. 2021

gpb

View full text Add to dashboard Cite

show abstract

“…Moreover, earlier age at onset and more prevalent medication indicate more severe symptoms, and fewer unmedicated patients compared to our group makes the results incomparable 32 . In the most recent study by Ottesen et al (2020) on a large group of monozygotoic twins with (n = 115), at risk (n = 49) or without (n = 40) affective disorders, no differences in S100B levels were noticed 33 .…”

Section: Discussionmentioning

confidence: 92%

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Rajewska‐Rager

Dmitrzak‐Węglarz

Kapelski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential role of S100B in mood disorders in adolescents and young adults . In a prospective two-year follow-up study, peripheral levels of S100B were investigated in 79 adolescent/young adult patients (aged 14–24 years), diagnosed with mood disorders and compared with 31 healthy control subjects. A comprehensive clinical interview was conducted which focused on clinical symptoms and diagnosis change. The diagnosis was established and verified at each control visit. Serum S100B concentrations were determined. We detected: lower S100B levels in medicated patients, compared with those who were drug-free, and healthy controls; higher S100B levels in a depressed group with a family history of affective disorder; correlations between age and medication status; sex-dependent differences in S100B levels; and lack a of correlation between the severity of depressive or hypo/manic symptoms. The results of our study indicate that S100B might be a trait-dependent rather than a state-dependent marker. Due to the lack of such studies in the youth population, further research should be performed. A relatively small sample size, a lack of exact age-matched control group, a high drop-out rate.

show abstract

“…This biomarker has gained much attention as a recent meta-analysis found that S100B was increased in schizophrenia spectrum disorders (24 studies; 1107 patients; standardized mean difference (SMD) = 0.82; 95% confidence interval (CI) = 0.51 to 1.13; I 2 = 90%), major depression (13 studies; 584 patients; SMD = 0.57; 95% CI = 0.31 to 0.83; I 2 = 73%) and bipolar disorder (4 studies; 142 patients; SMD = 0.55; 95% CI = 0.16 to 0.94; I 2 = 48%) (Futtrup et al 2020 ). However, the findings regarding a correlation between S100B and cognition derived from exploratory analysis in a cross-sectional study may have been without significance (Ottesen et al 2020 ). Thus, our data do not support a correlation between S100B and cognitive function.…”

Section: Discussionmentioning

confidence: 99%

“…There is scarce evidence regarding a possible association between the calcium-binding protein S100B and impaired cognition in bipolar disorder (Ottesen et al 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case–control study of patients with bipolar disorder and healthy control individuals

Knorr,

Simonsen,

Zetterberg

et al. 2024

Int J Bipolar Disord

Self Cite

View full text Add to dashboard Cite

Background Abnormalities in cerebrospinal fluid (CSF)-amyloid-beta (Aβ)42, CSF-Aβ40, CSF-Aβ38, CSF-soluble amyloid precursor proteins α and β, CSF-total-tau, CSF-phosphorylated-tau, CSF-neurofilament light protein (NF-L), CSF-neurogranin, plasma-Aβ42, plasma-Aβ40, plasma-total-tau, plasma-NF-L and, serum-S100B during affective episodes may reflect brain changes that could impact cognitive function in patients with bipolar disorder (BD). The study aimed to investigate the association between these biomarkers indicative of Alzheimer’s disease and those reflecting neurodegeneration alongside their impact on cognitive function in patients with BD and healthy control individuals (HC). The primary hypothesis was that GL and VL would increase with increasing levels of CSF-Aβ42 based on data from T0 and T3 in BD and HC jointly. Methods In a prospective, longitudinal case–control study euthymic patients with BD (N = 85) and HC (N = 44) were evaluated with clinical assessment and neuropsychological testing at baseline (T0) and during euthymia after a year (T3). Patients’ affective states were recorded weekly as euthymic, subthreshold level, major depression, or (hypo)mania. If an episode occurred during follow-up, the patient was also assessed in post-episode euthymia. Cognitive performance was measured as a global cognitive score (GL) for four cognitive domains including verbal learning and memory (VL). Results Estimated in a linear mixed model GL increased with 0.001 for each increase of 1 pg/ml of CSF-Aβ42 (97.5%, CI 0.00043–0.0018, adjusted-p = 0.0005) while VL increased by 0.00089 (97.5%, CI 0.00015–0.0018, adjusted-p = 0.045) in BD and HC jointly. The association was weak, however stronger in patients with BD compared to HC. Associations between other biomarkers including CSF-neurogranin, and cognitive domains were overall weak, and none remained significant after adjustment for multiple testing. Limitations Modest sample size. A complete data set regarding both CSF-AB-42 and cognitive test scores was obtained from merely 61 patients with BD and 38 HC individuals. Conclusion CSF-Aβ42 may be associated with cognitive dysfunction in patients with BD and HC individuals. The association appeared to be stronger in BD but with overlapping confidence intervals. Hence it remains uncertain whether the association is a general phenomenon or driven by BD.

show abstract

S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

Cited by 5 publications

References 53 publications

Evaluation of 5-HTTLPR (insertion/deletion) and BDNF (rs6265) genetic variations in the Slovakian individuals suffering from affective disorders

Evaluation of 5-HTTLPR (insertion/deletion) and BDNF (rs6265) genetic variations in the Slovakian individuals suffering from affective disorders

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case–control study of patients with bipolar disorder and healthy control individuals

Contact Info

Product

Resources

About